胃癌新辅助治疗的研究进展

Progress of neoadjuvant treatment for gastric cancer

胃癌是全球常见的恶性肿瘤之一,我国是胃癌高发地区,大多数患者在确诊时已处于进展期,此时胃癌根治性切除率低,且单纯的手术治疗即使进行根治性切除,预后仍较差。目前,为提高胃癌根治性切除率,改善胃癌预后,胃癌的治疗手段不再局限于单纯的手术治疗,进展期胃癌术前的新治疗模式已经出现,如新辅助化疗、新辅助放化疗、新辅助化疗联合靶向治疗等,这些治疗模式统称为新辅助治疗。新辅助治疗已逐渐成为进展期胃癌治疗的新方向,新辅助治疗可以使肿瘤降期并提高R_0切除率,降低局部复发率,从而改善预后,且越来越多的临床研究证明了新辅助治疗提高根治性切除率和改善预后的可行性。现对胃癌新辅助治疗的进展情况作一综述。

Gastric cancer is one of the most common malignancies in the world. China is one of the areas with high incidence of gastric cancer. Most people are already in advanced stage at the time of diagnosis with low radical resection rate, and even if radical resection is performed, the prognosis still remains poor. At present, in order to improve the rate of radical resection and the prognosis of gastric cancer, the treatment of gastric cancer is no longer limited to simple surgical treatment. New treatment methods of advanced gas tric cancer have emerged, such as neoadjuvant chemotherapy, neoadjuvant radiochemotherapy, neoadjuvant chemotherapy combined with targeted therapy, which are collectively referred to neoadjuvant therapy. Neoadjuvant therapy has gradually become a new direction of advanced gastric cancer treatment. Neoadjuvant therapy can downstage tumor and increase the rate of R resection to reduce the local 0 recurrence rate, thus improve prognosis. Clinical studies have proved the feasibility of neoadjuvant therapy in improving radical resec tion rate and prognosis. This paper reviews the recent progress of neoadjuvant therapy in gastric cancer.